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The large number of active combination chemotherapy regimens for most cancers has led to the need for better information to guide
the ‘standard’ treatment for each patient. In an attempt to individualise therapy, pharmacogenetics and pharmacogenomics (a
polygenic approach to pharmacogenetic studies) encompass the search for answers to the hereditary basis for interindividual
differences in drug response. This review will focus on the results of studies assessing the effects of polymorphisms in drug-
metabolising enzymes and drug targets on the toxicity and response to commonly used chemotherapy drugs. In addition, the need
for polygenic pharmacogenomic strategies to identify patients at risk for adverse drug reactions will be highlighted.
British Journal of Cancer (2004) 90, 8–11. doi:10.1038/sj.bjc.6601487 www.bjcancer.com
& 2004 Cancer Research UK
Keywords: pharmacogenetics; pharmacogenomics; polymorphism
                                
In the UK it has been estimated that approximately 7% of patients
are affected by adverse drug reactions (ADRs). Indeed, one out of
10 of all NHS bed days are used by patients with ADRs. These
ADRs result in the need for the equivalent of 15–20 400-bed
hospitals and cost about d380 million a year. ADRs due to cancer
chemotherapy are estimated to increase the overall hospital costs
by 1.9% and drug costs by 15% (Wiffen et al, 2002). Clearly, the
current regimen of ‘one dose fits all’ for chemotherapy treatment is
not ideal for patients and is not cost effective for the health service.
In an attempt to individualise therapy, pharmacogenetics and
pharmacogenomics (a polygenic approach to pharmacogenetic
studies) encompass the search for answers to the hereditary basis
for interindividual differences in drug response (Evans and
McLeod, 2003).
In addition to environmental influences, variation in the genetic
constitution between individuals will have a major impact on drug
activity. Single-nucleotide polymorphisms (SNPs) account for over
90% of genetic variation in the human genome. The remainder of
the variation is caused by insertions and deletions (indels), tandem
repeats and microsatellites. With the completion of the human
genome project, there has been an explosion in the discovery,
characterisation and validation of genetic variation. Over 1.42
million SNPs were initially identified through the human genome
project (Sachidanandam et al, 2001), and a goldmine of SNP
information is now readily accessible via publicly available
databases (Marsh et al, 2002). In addition, affordable, high
throughput genotyping technologies are now available, including
Pyrosequencing, FP-TDI, MALDI-TOF and SNP chips, making
pretreatment genotyping a real possibility. A comprehensive
review of the technology available to pharmacogenetics research
is beyond the scope of this minireview; however, there are many
excellent reviews describing these applications (Kwok, 2001; Shi,
2001; Syvanen, 2001; Freimuth et al, 2003).
Pharmacogenomics includes studies of variations in germline
DNA, somatic mutations and variations in RNA expression
(Watters and McLeod, 2003). This minireview will focus on the
impact of germline polymorphisms, highlighting their effects on
the activity and response to commonly used chemotherapy drugs
such as mercaptopurine, 5-fluorouracil, cyclophosphamide, plati-
num agents and camptothecins.
THIOPURINE METHYLTRANSFERASE (TPMT)
Perhaps the most compelling evidence for the utility of pharma-
cogenomic strategies to identify patients at risk for adverse drug
reactions comes from genetic polymorphisms in the gene (TPMT).
Mercaptopurine is a commonly used treatment for childhood acute
lymphocytic leukaemia. Thiopurine methyltransferase (TPMT)
methylates mercaptopurine, reducing its bioavailability for con-
version into thioguanine nucleotides (TGN), the cytotoxic form of
the drug. Approximately 10% of patients have an intermediate
enzyme activity and 0.3% are deficient for TPMT activity.
Intermediate-activity patients have a greater incidence of thiopur-
ine toxicity, whereas TPMT-deficient patients have severe or fatal
toxicity from mercaptopurine therapy. To date, at least 10
variations in the TPMT gene have been associated with low TPMT
enzyme activity (McLeod and Siva, 2002). Three of these variants
(TPMT*2, TPMT*3A and TPMT*3C) account for up to 95% of low
TPMT activity phenotypes. Patients heterozygous for these alleles
have intermediate TPMT levels and tolerate approximately 65% of
standard mercaptopurine dosage (Relling et al, 1999b). Patients
homozygous for the variant TPMT alleles are at high risk for
severe, sometimes life-threatening toxicity, requiring significant
reductions in drug doses (one out of 10 to one out of 15 of the
standard dose). Patients requiring dose reduction because of
variant TPMT alleles have similar or superior survival compared to
patients with the wild-type allele (Relling et al, 1999a). TPMT*3A is
the most common allele in Caucasian populations, with a
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are present in 0.2–0.8% of Caucasians. A significant variation in
TPMT allele frequencies is seen among different world popula-
tions. TPMT*3A is the only variation found in Southwest Asians
(1%), whereas all variant alleles in African populations are
TPMT*3C (5.4–7.6%) (McLeod and Siva, 2002). Pretreatment
knowledge of a patient’s TPMT genotype status is now being used
in major centres for dose optimisation, in order to reduce
prospectively the likelihood of adverse drug reactions in children
with ALL.
DIHYDROPYRIMIDINE DEHYDROGENASE (DPYD)
5-Fluorouracil (5FU) is one of the most commonly administered
chemotherapy agents, used in combination therapy for treatment
of colorectal, breast, head/neck and other solid tumours. Over 80%
of 5-FU is inactivated by dihydropyrimidine dehydrogenase
(DPD). Decreased DPD activity is associated with 4four-fold
risk of severe or fatal toxicity from standard doses of 5FU (Van
Kuilenburg et al, 2002). To date, at least 20 polymorphisms in the
DPD gene (DPYD) have been described (McLeod et al, 1998).
However, many of these polymorphisms have not been definitively
associated with altered DPD activity, and not all toxicity to
5FU from reduced DPD activity can be explained by the
currently known DPYD polymorphisms. The most consistent data
are for the allele DPYD*2A, a G4A splice site transition that
causes skipping of exon 14. Patients heterozygous for this
polymorphism have low DPD activity and toxicity to 5FU (Wei
et al, 1996). However, the allele frequency for DPYD*2A in control
populations appears to occur at a low frequency (approximately
one out of 135 in Caucasians) (McLeod et al, 1998) and a more
complete genotype–phenotype relationship study remains to
be completed. Currently, the apparently high false-negative rate
for DPYD as a predictor for severe 5FU toxicity (Collie-Duguid
et al, 2000) restricts the testing of DPYD*2A to either research
studies or as a component of a panel of oncology-related
pharmacogenetic markers.
UDP-GLUCURONOSYLTRANSFERASE 1A1 (UGT1A1)
Irinotecan, a camptothecin analogue, is used to treat colorectal,
lung and other solid tumours. 5FU/irinotecan combination therapy
is a common front-line therapy for colorectal cancer. The active
form of irinotecan, SN38, can be inactivated through glucuronida-
tion by a member of the UDP-glucuronosyltransferase family. A
dinucleotide repeat in a TATA box in the UGT1A1 promoter
results in altered UGT1A1 activity (Monaghan et al, 1996).
Reduced UGT1A1 is linked to a high risk (approximately four-
fold) of severe toxicity from irinotecan treatment, including dose-
limiting diarrhoea and neutropenia (Wasserman et al, 1997). The
variable number of TA repeats ranges from five to eight copies, six
TA repeats represent the most common allele, with up to 33% in
Caucasians having a variant allele containing seven repeats
(UGT1A1*28) (Iyer et al, 1999). Significant associations between
patients with the UGT1A1*28 allele and reduced UGT1A1
expression, and, consequently, reduced SN38 glucuronidation
have been shown in several studies (Ando et al, 1998; Iyer et al,
1999; Iyer et al, 2002). Assessment of the presence of the
UGT1A1*28 allele in patients prior to irinotecan treatment may
predict individuals at risk for severe toxicity from irinotecan,
allowing the selection of lower doses or alternative therapies.
GLUTATHIONE S-TRANSFERASE P1 (GSTP1)
Glutathiones play a role in detoxifying, and consequently
protecting cells from alkylating agents and products of reactive
oxidation. The pi-class of human (GSTP1) has been found to
catalyse glutathione conjugation of reactive metabolites from
cyclophosphamide, a drug commonly used in the treatment of
breast cancer and other solid tumours. In addition, GSTP1 is
known to detoxify platinum compounds, including oxaliplatin, a
relatively new chemotherapy drug used in combination with 5FU
for the treatment of advanced colorectal cancer.
A SNP causes an isoleucine to valine substitution at amino-acid
codon 105 (I105V) in the GSTP1 gene. The valine allele occurs at a
frequency of 33% in Caucasian populations, and is associated with
reduced GSTP1 activity compared to the isoleucine allele (Watson
et al, 1998). This SNP has been correlated with response to
cyclophosphamide chemotherapy treatment in breast cancer
patients (Sweeney et al, 2000). In all, 240 patients treated with
cyclophosphamide were characterised for the GSTP1 I105V SNP.
Patients homozygous for the valine (low activity) allele had a 0.3
hazard ratio (95% confidence interval 0.1–1.0) for overall survival
compared to patients homozygous for the isoleucine (high activity)
allele. Patients heterozygous for the SNP had an intermediate
hazard ratio for overall survival (0.8; 95% confidence interval 0.5–
1.3) (Sweeney et al, 2000). In addition, a study of 107 patients with
advanced colorectal cancer treated with a combination of 5FU and
oxaliplatin were assessed for the GSTP1 I105V SNP (Stoehlmacher
et al, 2002). Patients homozygous for the valine allele had a median
of 24.9 months survival, compared to 7.9 months for patients
homozygous for the isoleucine allele (Po0.001) (Stoehlmacher
et al, 2002).
Currently, studies are mainly focused on the effect of SNPs in
GSTP1 on the risk of cancer. Further research on the association of
GSTP1 SNPs with response to alkylating agents and platinum
drugs will provide information on the usefulness of prescreening
patients for GSTP1 genotypes prior to treatment. In addition,
genetic polymorphism in other genes involved in detoxification
and repair have been associated with response or survival after
platinum-containing chemotherapy (Park et al, 2001; Stoehlma-
cher et al, 2002), providing additional avenues for pharmacoge-
netic strategies to individualise therapy.
THYMIDYLATE SYNTHASE (TYMS)
So far, this minireview has focused on the effects of polymorph-
isms in drug-metabolising enzymes in response to a range of
chemotherapy drugs. Polymorphisms in drug targets are also an
important area for pharmacogenetic studies, as overexpression or
underexpression of drug targets could lead to resistance or toxicity
to standard chemotherapy regimens.
The main target for 5-FU is thymidylate synthase (TS).
Thymidylate synthase, together with a methyl cofactor, catalyses
the methylation of dUMP to dTMP. The 5FU metabolite FdUMP
forms a stable ternary complex with TS and the methyl cofactor,
blocking the production of dTMP and ultimately inhibiting DNA
synthesis. The overexpression of TS has been linked to resistance
to 5-FU and other TS inhibitors, such as raltitrexed. Three
polymorphisms have been described in the TS gene (TYMS). A
polymorphic 28bp tandem repeat in the promoter enhancer region
(TSER) has been extensively characterised in multiple world
populations (Marsh and McLeod, 2001a). The polymorphism
varies from two (TSER*2) to nine (TSER*9) copies of the tandem
repeat, with TSER*2 and TSER*3 being the most common alleles.
The higher numbers of repeats are mainly found in African
populations (Marsh et al, 2000), and their roles in TS expression
are currently unknown. In vitro studies have demonstrated that
TSER*3 has a higher TS expression than TSER*2 (Horie et al,
1995). In addition, small studies in cancer patients treated with
5FU have shown a correlation between TSER*3 and higher free TS
protein levels (Kawakami et al, 1999), TSER*3 and reduced
downstaging in rectal cancer (Villafranca et al, 2001) and TSER*3
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2001, Villafranca and colleagues studied the TSER in 65 rectal
cancer patients treated with chemoradiation. Over 60% of patients
with at least one TSER*2 allele had downstaging of their rectal
tumours (a marker of positive response to treatment), whereas
only 22% of patients homozygous for TSER*3 had tumour
downstaging (P¼0.002) (Villafranca et al, 2001). Large-scale
patient studies are now underway to better define the role of the
TSER polymorphism to outcome from 5FU chemotherapy.
However, a greater degree of resolution between ‘good’ and ‘poor’
outcome is needed to individualise therapy. It is likely that the
TSER genotype would be used in conjunction with other TYMS
variants and as part of a multiple gene panel in order to better
individualise therapy.
A SNP has recently been described within the second repeat
of the TSER*3 allele, which may also affect the level of TS
expression in patients by abolishing a USF1-binding site (Mandola
et al, 2003). Preliminary in vitro transfection assays have shown
the common allele (denoted 3RG), which occurs in 56% of
three repeat alleles in Caucasians (Mandola et al, 2003), to have a
higher translational efficiency than all other TSER alleles
(Kawakami and Watanabe, 2003). In addition, a study of
208 colorectal cancer patients and 675 controls found a 1.3-fold
(95% confidence intervals 0.9–1.9) increased risk of colorectal
cancer for patients with the 3RG allele, implying that the
polymorphism may enhance the effects of the repeat polymorph-
ism in the TSER (Stoehlmacher et al, 2003). A full functional
analysis of this SNP, and a large-scale study in 5FU-treated
patients, is now warranted.
A third polymorphism in the TYMS gene is a 6bp deletion
located in the 30UTR, 447bp downstream from the stop codon
(Ulrich et al, 2000). The deletion is present at an allele frequency
of 27% in Caucasians (Lenz et al, 2002). Recent data suggest
a significant association of the deletion allele with a reduced
response to 5FU-containing chemotherapy. Patients homozygous
for the presence of the 6bp sequence had an odds ratio of 2.0
for response to 5FU-containing combination chemotherapy
(McLeod et al, 2003). A large-scale assessment of the role of each
TYMS polymorphism individually and as a haplotype is
now required to determine whether prospective assessment is
warranted in patients prior to 5FU-containing chemotherapy
treatment.
POLYGENIC PHARMACOGENOMIC STRATEGIES
The examples highlighted in this review demonstrate the possible
utility in prescreening patients for well-characterised polymorph-
isms to enable the best-tolerated and most effective treatment
strategies to be identified. Unfortunately, genes do not act in
isolation and drugs are often involved in complex metabolic
pathways in the cell before they are converted to active or inactive
forms. A clear example is seen with 5-FU, which utilises the cell’s
pyrimidine metabolic pathway (Figure 1). Variations in the DPYD
gene can determine the amount of 5FU available for conversion to
FdUMP, and variations in the TYMS gene can determine the
amount of target available for inhibition by FdUMP. However,
there are over 29 genes involved in the 5FU pathway (Figure 1), in
which genetic variations in any or all can contribute to systemic
toxicity or anti-tumour response. Initial steps are being taken to
integrate drug pathway analysis, rather than single-gene studies,
into clinical trials to assess the predictive power of chemotherapy
activity and response. This will allow for the evaluation of gene–
gene interactions in the context of anticancer drug effect. Drug
pathway profiling in advance of therapy may allow us a greater
chance to achieve the goal of optimising chemotherapy strategies.
One can envision a future whereby comprehensive assessment of
genetic variants in components of drug pathways for all approved
anticancer drugs will be conducted at diagnosis. This would allow
the selection of therapy that will be well tolerated and maximally
efficacious. To enable this, a significant enhancement in our
current understanding of the functional importance of the many
genetic variants in drug pathway genes is required, in order to
avoid the common finding of ‘polymorphism of unknown
consequence’. Thus it is imperative that current active and
planned clinical trials include correlative science components, in
order to define clearly the relative contribution of pharmacoge-
netics to optimisation of chemotherapy.
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